Early trial tests new combo for Tough-to-Treat blood cancers
NCT ID NCT05065866
Summary
This early-stage study aimed to find a safe dose of a new drug combination (BMS-986345 plus duvelisib) for patients with advanced blood cancers like lymphoma and leukemia. It involved 14 adults whose cancers had progressed after other treatments. The main goal was to check for side effects and determine the highest dose patients could tolerate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.